Factors influencing skin autofluorescence of patients with peritoneal dialysis

Acta Physiologica Hungarica

Volumn 99, Issue 2, 2012, Pages 216-222

  MacSai E ^a   Benke, A ^a   Cseh, A ^b   Vasarhelyi B ^c  

^a Csolnoky Hospital   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Icodextrin; Peritoneal dialysis; Skin autofluorescence

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DIANEAL; EXTRANEAL; GLUCOSE; ICODEXTRIN; PERITONEAL DIALYSIS FLUID;

ADULT; AGE; AGED; ARTICLE; AUTOFLUORESCENCE; BODY MASS; CARDIOVASCULAR RISK; DIABETES MELLITUS; FEMALE; HUMAN; KIDNEY FAILURE; LABORATORY DEVICE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NON INVASIVE PROCEDURE; PERITONEAL DIALYSIS; SIDE EFFECT; SKIN AUTOFLUORESCENCE; SMOKING HABIT; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DIABETIC NEPHROPATHIES; DIALYSIS SOLUTIONS; FEMALE; FLUORESCENCE; GLUCANS; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HUNGARY; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERITONEAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; SKIN; UP-REGULATION;

EID: 84864666440     PISSN: 0231424X     EISSN: 15882683     Source Type: Journal    
DOI: 10.1556/APhysiol.99.2012.2.15     Document Type: Article

References (19)

1. Blake PG: Should nonglucose containing peritoneal dialysis solutions be used in all patients to avoid long-term membrane injury? Semin. Dial. 24 (4), 450-451 (2011)
2. Bruschi M, Candiano G, Santucci L, Petretto A, Mangraviti S, Canepa A, Perri K, Ghiggeri GM, Verrina E: Proteome profile of peritoneal effluents in children on glucose-or icodextrin-based peritoneal dialysis. Nephrol. Dial. Transplant. 26 (1), 308-316 (2011)
3. Daroux M, Prévost G, Maillard-Lefebvre H, Gaxatte C, D'Agati VD, Schmidt AM, Boulanger E: Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies. Diabetes Metab. 36 (1), 1-10 (2010)
4. García-López E, Lindholm B: Icodextrin metabolites in peritoneal dialysis. Perit. Dial. Int. 29 (4), 370-376 (2009)
5. Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ, Gans RO, Bilo HJ: Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 31 (3), 517-521 (2008)
6. Gerrits EG, Smit AJ, Bilo HJ: AGEs, autofluorescence and renal function. Nephrol. Dial. Transplant. 24 (3), 710-713 (2009)
7. Holmes CJ: Reducing cardiometabolic risk in peritoneal dialysis patients: role of the dialysis solution. J. Diabetes Sci. Technol. 3 (6), 1472-1480 (2009)
8. Kim YL: Can we overcome the predestined poor survival of diabetic patients? Perspectives from pre-and postdialysis. Perit. Dial. Int. 27 (Suppl. 2), S171-175 (2007)
9. Kuriyama S: Peritoneal dialysis in patients with diabetes: are the benefits greater than the disadvantages? Perit. Dial. Int. 27 (Suppl. 2), S190-195 (2007) (Pubitemid 350047700)
10. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, Smit AJ: Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 29 (12), 2654-2659 (2006) (Pubitemid 44912194)
11. Lutgers HL, Gerrits EG, Graaff R, Links TP, Sluiter WJ, Gans RO, Bilo HJ, Smit AJ: Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 52 (5), 789-797 (2009)
12. McIntyre NJ, Chesterton LJ, John SG, Jefferies HJ, Burton JO, Taal MW, Fluck RJ, McIntyre CW: Tissueadvanced glycation end product concentration in dialysis patients. Clin. J. Am. Soc. Nephrol. 5 (1), 51-55 (2010)
13. McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW: Skin Autofluorescence and the Association with Renal and Cardiovascular Risk Factors in Chronic Kidney Disease Stage 3. Clin. J. Am. Soc. Nephrol. Sept. 1. (2011)
14. Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans RO, Smit AJ: Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J. Am. Soc. Nephrol. 16 (12), 3687-3693 (2005) (Pubitemid 46211290)
15. Meerwaldt R, Zeebregts CJ, Navis G, Hillebrands JL, Lefrandt JD, Smit AJ: Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Am. J. Kidney Dis. 53 (1), 138-150 (2009)
16. Portolés J, Corchete E, López-Sánchez P, Coronel F, Ocaña J, Ortiz A; Miembros del GCDP: Patients on peritoneal dialysis with type 2 diabetes have poorer outcomes than non-diabetics due to preceding cardiovascular comorbidity. Nefrología 29 (4), 336-342 (2009)
17. Schmitt CP, von Heyl D, Rieger S, Arbeiter K, Bonzel KE, Fischbach M, Misselwitz J, Pieper AK, Schaefer F; for the Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS): Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content. Nephrol. Dial. Transplant. 22 (7), 2038-2044 (2007) (Pubitemid 47244779)
18. Skubala A, Zywiec J, Zełobowska K, Gumprecht J, Grzeszczak W: Continuous glucose monitoring system in 72-hour glucose profile assessment in patients with end-stage renal disease on maintenance continuous ambulatory peritoneal dialysis. Med. Sci. Monit. 16 (2), CR75-83 (2010)
19. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T, Ritz E: Glucose degradation products in PD fl uids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int. 63 (1), 298-305 (2003) (Pubitemid 35463934)